Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 250

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 250
---
ICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  Material                         

  Research and Development  

Research
costs are charged to operations as incurred. Development activities involve a plan or design for the production of new or substantially
improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product
is technically and commercially feasible, future economic benefits are probable, and the Company intends to or has sufficient resources
to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labor and overhead
costs that are directly attributable to preparing the asset for its intended use and borrowing costs on qualifying assets. Other development
expenditures are recognized in the consolidated statement of operations and comprehensive loss as incurred. The Company has not capitalized
any development costs for the years ended October 31, 2024, 2023 and 2022.

  Loss Per Share  

Basic
loss per share is computed using the weighted average number of common shares outstanding during the period. The treasury stock method
is used for the calculation of diluted loss per share, whereby all “in the money” stock options and share purchase warrants
are assumed to have been exercised at the beginning of the period and the proceeds from their exercise are assumed to have been used
to purchase common shares at the average market price during the period. When a loss is incurred during the period, basic and diluted
loss per share is the same as the exercise of stock options and share purchase warrants is considered to be anti-dilutive. As of October
31, 2024, the Company had 2,819,173 833,810 26,419

  The Company capitalizes certain legal and other third-party fees that are directly related to the Company’s in- process equity financing until such financing is consummated. After consummation ...  

  New and amended IFRS accounting standards that are effective for the current year  
 ─────────────────────────────────────────────────────────────────────────────────────

  Amendments to IAS 1 Presentation of Financial Statements— Classification  
  of Liabilities as Current or Non-current                                  
 ────────────────────────────────────────────────────────────────────────────

The
IASB issued a narrow-scope amendment to IAS 1, in January 2020, to clarify that liabilities are classified as either current or non-current,
depending on the rights that exist at the end of the reporting period